Navigation Links
WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board
Date:11/5/2009

dation.

Forward-Looking Statements

This press release contains certain "forward-looking statements". Such statements include statements relating to the expected benefits to the company of Dr. Sears' appointment to the company's Scientific Advisory Board, the expected benefits of the SmartChip technology to other applications, and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, inc
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
7. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
8. WaferGen Announces Signing of Two Private Placements
9. WaferGen to Present at the Ninth Annual Beyond Genome Conference
10. WaferGen Announces Second Quarter 2008 Financial Results
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... 2015 YourEncore, an Indianapolis, Indiana-based ... consumer products and food sciences industries solve complex ... for Clinical Research Excellence and Safety (ACRES), a ... clinical research, have partnered to speed innovation in ... YourEncore brings to ACRES experts with proven experience, ...
(Date:4/20/2015)... , April 20, 2015 Orthobiologics ... healing bone injuries. The orthobiologics market is a rewarding ... its stakeholders. The global orthobiologics market report defines and ... revenue. The global orthobiologics market was valued at $5,712.4 ... million by 2019, at a CAGR of 6.7% from ...
(Date:4/20/2015)...  "Everybody is affected by cancer sooner or later," ... brutal. We,ve got to get away from that."  If ... a loved one or friend battling for their life ... and other treatments cause the human body. It,s almost ... and succumb to the disease. Dr. Dionne has developed ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... II study of 20 patients reported in Annals ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) today ... of a limited phase II study of CHOP ... Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60,years of ...
... 4 Vermillion, Inc.,(Nasdaq: VRMLD ), a ... diagnostic test programs and provided a preview,of key ... course of 2008. The,Company also released financial results ... 2007., "In 2007, Vermillion made significant clinical ...
... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time,members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: ... the company,s recent,transactions targeting cleaning up the capital structure, and upcoming,product and sales milestones., ... Conference Call Numbers ... Wednesday, ...
Cached Biology Technology:CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... working on the fundamental biological processes of plants could ... many parts of the world. Using model plant species, ... uncovered one of the processes used by the plants ... discoveries are now being applied to improve the productivity ...
... geochemists from the University of Southern California and Rice ... that could power spy drones that fit in the ... long been interested in micro-scale air vehicles ?some as ... the lack of a suitable, compact power source. With ...
... at the Max Planck Institute of Biochemistry in Martinsried, ... that blocking blood vessel development in a tumour slows ... principle led to the development of SUTENT®, whose active ... use in the United States, and it is expected ...
Cached Biology News:Sun protection for plants 2USC, Rice to develop bacteria-powered fuel cells 2Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... The Jouan RC Sensitive Bio (for heat-labile ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: